(1) Nature and quantity of the product to be purchased:
1) Pembrolizumab (Genetical Recombination)
100 mg 4 mL 1 vial 686 vials
2) Nivolumab (Genetical Recombination)
240 mg 24 mL 1 vial 302 vials
3) Bevacizumab (Genetical Recombination)
400 mg 16 mL 1 vial 411 vials
4) Eculizumab (Genetical Recombination)
300 mg 30 mL 1 vial 156 vials
5) Somatropin (Genetical Recombination)
12 mg 1 cartridge 1,080 cartridges
6) Atezolizumab (Genetical Recombination)
1200 mg 20 mL 1 vial 151 vials
7) Palivizumab (Genetical Recombination)
100 mg 1 mL 1 vial 565 vials
8) Golimumab (Genetical Recombination)
50 mg 0.5 mL 1 injector 310 injectors
9) Durvalumab (Genetical Recombination)
120 mg 2.4 mL 1 vial 836 vials
10) Pemetrexed Sodium Hydrate
500 mg 1 vial 249 vials
11) Pertuzumab (Genetical Recombination)
420 mg 14 mL 1 vial 273 vials
(2) Deadline for the submission of application forms and relevant
documents for qualification:
August 20, 2020 at 10:00 a.m.
(3) Deadline for the submission of tenders via the electronic
bidding system and submission of tenders in person:
September 18, 2020 at 10:00 a.m.
(Bids through the mail should arrive by September 17, 2020 at
5:00 p.m.)
(4) Contact point for the notice:
Management Section, Management Planning Division,
Management Planning Department, Hospital Bureau, City of Nagoya
1-1, Sannomaru 3-chome, Naka-ku, NAGOYA 460-8508 Japan